Ignite Creation Date:
2025-12-24 @ 3:52 PM
Ignite Modification Date:
2026-02-01 @ 5:32 PM
Study NCT ID:
NCT04353492
Status:
COMPLETED
Last Update Posted:
2025-11-12
First Post:
2020-04-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsing Multiple Sclerosis | View |